Human Growth Hormone (hGH) Market Size to Surpass USD 9,211.73 Mn by 2030

The global Human Growth Hormone (hGH) market was estimated at USD 3,865.4 million in 2021 and it is expected to surpass around USD 9,211.73 million by 2030, poised to grow at a CAGR of 10.13% from 2022 to 2030.

Key Findings of the Study

• By application, the Turner Syndrome segment dominated the human growth hormone market in 2020 and is anticipated to continue the same during the forecast period.
• By region, North America was the major shareholder and accounted for the highest share of 49% in 2020.
• By route of administration, the subcutaneous segment is expected to grow at a CAGR of 9.3% during the forecast period.
• By distribution channel, the hospital pharmacy segment dominated the market in 2020 and is anticipated to maintain its dominance during the forecast period.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39338

The human growth hormone also known as somatotropin is a peptide hormone secreted by the pituitary gland that regulates cell growth, cell regeneration and repair, reproduction, and metabolism that contributes to complete human growth. Growth hormone levels in the human body should be suitable for normal growth and can be controlled by factors such as exercise, sleep, stress, and low glucose levels. Human growth hormones also help regulate body composition, muscle growth & bone growth, body fluids, sugar & fat metabolism, and recovery from injury. It also helps increase muscle strength and performance.

In humans, a deficiency of growth hormone is caused when the pituitary gland does not include adequate concentration of human growth hormone. This deficiency is treated by injecting human growth hormone with a subcutaneous injection. Various genetic disorders such as Prader-Willi syndrome and Turner syndrome can also cause growth hormone deficiency, resulting in delayed puberty and shorter height than averages.

Turner syndrome, also known as congenital ovarian hypoplasia syndrome, occurs when the X chromosome is partially or completely lost in women. Turner syndrome (TS) is the most common type of human chromosomal aberration that occurs at 1:2,500 live births.

Human growth hormone helps promote regeneration, reproduction, and growth. Increased use of growth hormone and growth hormone awareness, which helps in the management of hormonal imbalance disorders, enhances the market growth.

In addition, many companies are investing in R&D to develop a growth hormone that has fewer side effects and will be a long-term treatment. The growth in the market is due to the increase in diseases related to growth hormone deficiency, rise in use of aging hormones, efforts taken by governments and various private organizations to spread awareness of growth hormone deficiency, and strong productivity. Other factors such as increased awareness of the treatment process, increased number of health disorders, and increased neuropsychiatric cases are projected to improve the growth of the human growth hormone market. The rapid growth of new human growth hormone novels is expected to drive the human growth hormone market growth.

The COVID-19 outbreak is anticipated to impact the global human growth hormone market. As per an article from Frontiers, the patients with decreased growth hormone secretion present a risk factor for COVID-19, which requires attention that will help in the prevention of COVID-19. Along with this, patients who are suffering from Prader-Willi syndrome also need to take enough care to minimize the risk of getting COVID-19. Moreover, Prader-Willi syndrome patients may not show typical symptoms such as a high temperature and they may also experience a higher-than-normal pain threshold which may delay in the diagnosis of COVID-19. Individuals with Turner syndrome are at higher risk for severe illness from the COVID-19 virus. The COVID-19 pandemic has stressed and impacted the healthcare systems of the world. The lockdown situation all over the world, has created obstacles for both the patients and the healthcare providers.

Scope of The Report

Human Growth Hormone Market Segmentation  

The human growth hormone market is segmented on the basis of application, route of administration, distribution channel, and region. On the basis of application, the market is divided into Growth hormone deficiency, Prader-willi syndrome, Turner syndrome, Small for gestational age (SGA), and Others. On the basis of route of administration, the market is divided into oral, intravenous, intramuscular, and subcutaneous. On the basis of distribution channel, the market is fragmented into hospital pharmacy, retail pharmacy, and online pharmacy.

Segment review 

On the basis of application, the human growth hormone market is divided into growth hormone deficiency, Prader Willi syndrome, Turner syndrome, small for gestational age, idiopathic short stature, and others. The Turner syndrome segment held a major share in the human growth hormone market in 2020 and is expected to continue the trend during the forecast period. This is attributed to the increase in incidence of Turner syndrome across the globe. Further, this syndrome affects 1 female in 2,000 to 2,500 live female births,

On the basis of administration, the market is categorized into oral, intravenous, subcutaneous, and intramuscular. The subcutaneous route of administration segment held a major share in the human growth hormone market in 2020 and is expected to continue the trend during the forecast period. This is attributed to the fact that when injected subcutaneously, the hormone is majorly absorbed in the cells, which is beneficial for the patients.

On the basis of distribution channel, the market is segregated into hospital pharmacy, retail pharmacy, clinics, and online pharmacy. The hospital pharmacy segment dominated the global human growth hormone market in 2020 and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the preference and ease of availability of artificial or recombinant human growth hormone in hospital pharmacies.

Region segment review

Region-wise, North America dominated the market in 2020, owing to the factors like rise in geriatric population, presence of many market giants, and new research to develop innovative recombinant human growth hormone. However, Asia-Pacific is expected to register the highest CAGR in terms of revenue during the forecast period, owing to the increase in population and rise in awareness amongst the population. Along with this, there has been progress in the economic situation of the continent and growth in healthcare infrastructure.

Prominent players in the market report include Novo Nordisk, Merck & Co., Eli Lilly & Company, Pfizer Inc., Teva Pharmaceutical Industries, Novartis AG, Anhui Anke Biotechnology (Group) Co., Ltd., Roche, Ipsen, and Ferring BV.

Key Players

• Novo Nordisk
• Merck & Co.
• Eli Lilly And Company
• Pfizer Inc.
• TEVA PHARMACEUTICAL INDUSTRIES.
• Novartis AG
• Anhui Anke Biotechnology (Group) Co., Ltd.
• Roche
• Ipsen
• Ferring BV

Market Segments

By Application

• Growth hormone deficiency
• Prader-Willi syndrome
• Turner syndrome
• Small for gestational age (SGA)
• Others

By Route of Administration

• Oral
• Intravenous
• Intramuscular
• Subcutaneous

By Distribution Channel

• Hospital pharmacy 
• Retail pharmacy 
• Online Pharmacy

By Region

• North America
• Europe
• Asia-Pacific
• LAMEA

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39338

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333